Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

906 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
Schöffski P, Wozniak A, Escudier B, Rutkowski P, Anthoney A, Bauer S, Sufliarsky J, van Herpen C, Lindner LH, Grünwald V, Zakotnik B, Lerut E, Debiec-Rychter M, Marréaud S, Lia M, Raveloarivahy T, Collette S, Albiges L. Schöffski P, et al. Among authors: wozniak a. Eur J Cancer. 2017 Dec;87:147-163. doi: 10.1016/j.ejca.2017.10.014. Epub 2017 Nov 14. Eur J Cancer. 2017. PMID: 29149761 Clinical Trial.
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients.
Maertens O, Prenen H, Debiec-Rychter M, Wozniak A, Sciot R, Pauwels P, De Wever I, Vermeesch JR, de Raedt T, De Paepe A, Speleman F, van Oosterom A, Messiaen L, Legius E. Maertens O, et al. Among authors: wozniak a. Hum Mol Genet. 2006 Mar 15;15(6):1015-23. doi: 10.1093/hmg/ddl016. Epub 2006 Feb 6. Hum Mol Genet. 2006. PMID: 16461335
Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).
Rutkowski P, Nowecki ZI, Debiec-Rychter M, Grzesiakowska U, Michej W, Woźniak A, Siedlecki JA, Limon J, vel Dobosz AJ, Kakol M, Osuch C, Ruka W. Rutkowski P, et al. Among authors: wozniak a. J Cancer Res Clin Oncol. 2007 Sep;133(9):589-97. doi: 10.1007/s00432-007-0202-4. Epub 2007 Apr 26. J Cancer Res Clin Oncol. 2007. PMID: 17458563
Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor.
Rutkowski P, Nowecki ZI, Michej W, Debiec-Rychter M, Woźniak A, Limon J, Siedlecki J, Grzesiakowska U, Kakol M, Osuch C, Polkowski M, Głuszek S, Zurawski Z, Ruka W. Rutkowski P, et al. Among authors: wozniak a. Ann Surg Oncol. 2007 Jul;14(7):2018-27. doi: 10.1245/s10434-007-9377-9. Epub 2007 May 2. Ann Surg Oncol. 2007. PMID: 17473953
Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
Rutkowski P, Debiec-Rychter M, Nowecki ZI, Wozniak A, Michej W, Limon J, Siedlecki JA, Jerzak Vel Dobosz A, Grzesiakowska U, Nasierowska-Guttmejer A, Sygut J, Nyckowski P, Krawczyk M, Ruka W. Rutkowski P, et al. Among authors: wozniak a. Med Sci Monit. 2007 Nov;13(11):CR515-522. Med Sci Monit. 2007. PMID: 17968300
906 results